Diabetic Autonomic Neuropathy Management

Pathophysiology and Diagnosis

Diabetic autonomic neuropathy is a heterogeneous disorder affecting multiple organ systems, including cardiovascular, gastrointestinal, genitourinary, and sudomotor functions, according to the American Diabetes Association 3, 1
Screening for autonomic neuropathy should begin at diagnosis of type 2 diabetes and 5 years after diagnosis of type 1 diabetes, as recommended by the American Diabetes Association 1, 4
Diagnosis involves assessing symptoms such as orthostatic dizziness, syncope, dry cracked skin, resting tachycardia, and evidence of peripheral dryness, with a strength of evidence Grade B 1
Cardiovascular autonomic neuropathy is diagnosed through heart rate variability testing and is associated with increased mortality independent of other cardiovascular risk factors, as reported by the American Heart Association 2, 5

Optimize glucose control to prevent or delay development of neuropathy in type 1 diabetes (Grade A evidence) and slow progression in type 2 diabetes (Grade B evidence), according to the American Diabetes Association 2, 6
Near-normal glycemic control implemented early in the course of diabetes is most effective for preventing diabetic autonomic neuropathy, especially in type 1 diabetes, with a strength of evidence Grade A 6

First-line pharmacologic treatments include pregabalin (100 mg three times daily), duloxetine (60-120 mg daily), and gabapentin (300-1,200 mg three times daily), as recommended by the American Academy of Neurology 3, 2
Alternative options include tricyclic antidepressants (amitriptyline, nortriptyline, imipramine at 10-75 mg at bedtime) and capsaicin cream (0.025-0.075% applied three to four times daily), with a strength of evidence Grade B 3, 7

Treatment focuses on alleviating symptoms, such as orthostatic hypotension and resting tachycardia, with careful cardiac evaluation, as recommended by the American College of Cardiology 2, 8
Management of resting tachycardia may require careful cardiac evaluation, with a strength of evidence Grade C 5, 9

Gastroparesis treatment includes prokinetic drugs and dietary modifications (small, frequent meals, low fat, low fiber), as recommended by the American Gastroenterological Association 6
Evaluate gastric emptying if symptoms are suggestive, with a strength of evidence Grade B 3, 6

Up to 50% of diabetic peripheral neuropathy may be asymptomatic, requiring proactive screening, as reported by the American Diabetes Association 2, 4
Diabetic neuropathy is a diagnosis of exclusion, and other potential causes of neuropathy should be considered, such as alcohol toxicity, vitamin B12 deficiency, hypothyroidism, and renal disease, with a strength of evidence Grade B 2, 8
Cardiovascular autonomic neuropathy significantly increases mortality risk and requires careful monitoring, as recommended by the American Heart Association 5, 9

Annual assessment for progression of autonomic neuropathy is recommended, as suggested by the American Diabetes Association 1, 2
Regular foot examinations for patients with concurrent peripheral neuropathy, with a strength of evidence Grade B 3, 2
Monitor for hypoglycemia unawareness, which can be a manifestation of autonomic neuropathy, as reported by the American Diabetes Association 2, 4
Assess treatment efficacy based on symptom improvement and quality of life, with a strength of evidence Grade C 3, 1